- Home
- GBIO vs ME Comparison
GBIO vs ME Comparison
Compare GBIO & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- ME
- Stock Information
- Founded
- GBIO 2016
- ME 2006
- Country
- GBIO United States
- ME United States
- Employees
- GBIO N/A
- ME N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- ME Precision Instruments
- Sector
- GBIO Health Care
- ME Health Care
- Exchange
- GBIO Nasdaq
- ME Nasdaq
- Market Cap
- GBIO 64.8M
- ME 98.7M
- IPO Year
- GBIO 2020
- ME N/A
- Fundamental
- Price
- GBIO $0.88
- ME $3.39
- Analyst Decision
- GBIO Strong Buy
- ME Hold
- Analyst Count
- GBIO 2
- ME 1
- Target Price
- GBIO $6.50
- ME $9.40
- AVG Volume (30 Days)
- GBIO 581.0K
- ME 219.4K
- Earning Date
- GBIO 03-05-2025
- ME 02-05-2025
- Dividend Yield
- GBIO N/A
- ME N/A
- EPS Growth
- GBIO N/A
- ME N/A
- EPS
- GBIO N/A
- ME N/A
- Revenue
- GBIO $18,582,000.00
- ME $193,260,000.00
- Revenue This Year
- GBIO $212.74
- ME $21.93
- Revenue Next Year
- GBIO N/A
- ME $17.31
- P/E Ratio
- GBIO N/A
- ME N/A
- Revenue Growth
- GBIO 514.08
- ME N/A
- 52 Week Low
- GBIO $0.75
- ME $2.66
- 52 Week High
- GBIO $4.65
- ME $16.52
- Technical
- Relative Strength Index (RSI)
- GBIO 28.66
- ME 44.56
- Support Level
- GBIO $0.85
- ME $3.15
- Resistance Level
- GBIO $1.01
- ME $4.18
- Average True Range (ATR)
- GBIO 0.12
- ME 0.26
- MACD
- GBIO 0.00
- ME 0.05
- Stochastic Oscillator
- GBIO 7.50
- ME 29.46
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.